|Bid||182.01 x 900|
|Ask||183.57 x 1200|
|Day's range||181.19 - 184.58|
|52-week range||121.98 - 212.00|
|Beta (5Y monthly)||0.96|
|PE ratio (TTM)||N/A|
|Earnings date||09 Feb 2022 - 14 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||207.10|
CAMBRIDGE, Mass., November 23, 2021--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:
The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.
Shares of Dicerna Pharmaceuticals (NASDAQ: DRNA), a clinical-stage biopharmaceutical company, are exploding higher today in response to a buyout offer from Novo Nordisk (NYSE: NVO). Today, Novo Nordisk agreed to acquire all of Dicerna's outstanding shares for $38.25 each. At the moment, Dicerna's pipeline has a handful of midstage candidates and one in late-stage trials called nedosiran.